Stockscreener 앱 받기
0.2146
2.19%
0.0046
전일 마감가:
$0.21
열려 있는:
$0.2012
하루 거래량:
2.39M
Relative Volume:
0.72
시가총액:
$37.27M
수익:
-
순이익/손실:
$-16.76M
주가수익비율:
-2.6825
EPS:
-0.08
순현금흐름:
$-132.97M
1주 성능:
-14.16%
1개월 성능:
-41.33%
6개월 성능:
-65.45%
1년 성능:
-85.40%
1일 변동 폭
$0.1905
$0.2146
1주일 범위
$0.1905
$0.25
52주 변동 폭
$0.1905
$1.45
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
명칭
X 4 Pharmaceuticals Inc
전화
857-529-8300
주소
61 NORTH BEACON STREET, BOSTON, MA
XFOR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
0.2146 | 37.27M | 0 | -16.76M | -132.97M | -0.08 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-12-12 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2023-08-30 | 재개 | B. Riley Securities | Buy |
| 2022-12-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-12-12 | 개시 | Piper Sandler | Overweight |
| 2019-12-23 | 개시 | Oppenheimer | Outperform |
| 2019-12-18 | 개시 | ROTH Capital | Buy |
| 2019-12-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-12-05 | 개시 | B. Riley FBR | Buy |
| 2019-06-07 | 개시 | Stifel | Buy |
| 2019-06-05 | 개시 | Cowen | Outperform |
모두보기
X 4 Pharmaceuticals Inc 주식(XFOR)의 최신 뉴스
Now Pharma Inc looks for cure as Trump delivers dose of anxiety - The Economic Times
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Layoff Tracker: Relay Will Cut 70 Employees, Affecting Research Budget by 75% - BioSpace
Crescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class Oncology Therapeutics - Quantisnow
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti™ for the Treatments of Acute Bipolar I Disorder and Schizophrenia - BioSpace
Fierce Biotech Layoff Tracker 2025: Sail cuts staff; Carisma and Inspirna shutter - Fierce Biotech
Ionis to present at upcoming investor conferences - Quantisnow
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q4 2024 Earnings Call Transcript - MSN
Research Analysts Issue Forecasts for XFOR FY2028 Earnings - Defense World
X4 Pharmaceuticals (NASDAQ:XFOR) Receives “Buy” Rating from HC Wainwright - Defense World
XFOR: Full Enrollment of Phase 3 4WARD Trial Expected in 2H25… - Yahoo Finance
Breaking Down X4 Pharmaceuticals: 4 Analysts Share Their Views - Benzinga
H.C. Wainwright maintains Buy on X4 Pharma, target at $1.50 - Investing.com
X4 Pharmaceuticals Inc (XFOR) Q4 2024 Earnings Call Highlights: - GuruFocus
X4 Pharmaceuticals Inc (XFOR) Q4 2024 Earnings Call Highlights: Strategic Restructuring and ... - Yahoo Finance
X4 Pharmaceuticals Inc (XFOR) Q4 2024 Earnings Call Highlights: Strategic Restructuring and ... By GuruFocus - Investing.com Canada
Stifel cuts X4 Pharmaceuticals target to $3, maintains buy rating - Investing.com
Brookline maintains Buy on X4 Pharma, keeps $4 price target By Investing.com - Investing.com UK
X4 Pharmaceuticals: Q4 Earnings Snapshot - The Washington Post
Earnings call transcript: X4 Pharmaceuticals Q4 2024 misses EPS forecast - Investing.com
X4 Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
X4 Pharmaceuticals Inc (XFOR) Q4 2024 Earnings: Revenue Surpasses Estimates at $1.4M, EPS Misses at -$0.20 - GuruFocus
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - The Manila Times
X4 Pharmaceuticals Announces Activation of Phase 3 4WARD Trial for Chronic Neutropenia and 2024 Financial Results - Nasdaq
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is favoured by institutional owners who hold 70% of the company - Yahoo Finance
X4 Pharmaceuticals Inc (XFOR) Q4 2024 Earnings Report Preview: What To Look For - Yahoo Finance
X4 Pharmaceuticals Inc (XFOR) Q4 2024 Earnings Report Preview: W - GuruFocus
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
X4 Pharmaceuticals Inc expected to post a loss of 17 cents a shareEarnings Preview - TradingView
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Prescription Drug Costs | Pros, Cons, Debate, Arguments, Economy, Laws, Government, & Regulation - Britannica
SEC Form 10-K filed by Sionna Therapeutics Inc. - Quantisnow
Form 10-K Sionna Therapeutics, For: Dec 31 - StreetInsider.com
This Pharmaceutical Company Completes 100 per cent Acquisition of Antibe Therapeutics for CAD 4.5 Million - Dalal Street Investment Journal
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Short Interest Update - Defense World
Alkaptonuria Therapeutics Market to Reach US$ 31.6 Million - GlobeNewswire
Breast Cancer Clinical Pipeline | 100+ Companies, Including - openPR
Is Now The Time To Buy X4 Pharmaceuticals Inc (NASDAQ: XFOR) Stock? - Stocks Register
X4 Pharmaceuticals (XFOR) Expected to Announce Quarterly Earnings on Tuesday - Defense World
X 4 Pharmaceuticals Inc (XFOR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.01%
자본화:
|
볼륨(24시간):